REG-4basebio Plc: Synthetic opDNA® utilised in Phase I/II US clinical trials

4BasebioAnnouncement

Today 07:02

27 October 2025

4basebio PLC

("4basebio" or the "Company")

Synthetic                                                                     
                                      opDNA®                                 
                                                                         
utilised in Phase I/II US clinical trials

Global pharma partner initiates mRNA therapy trial using 4basebio’s opDNA®
template, marking a key milestone in synthetic DNA adoption for advanced
genetic medicines

Cambridge, UK, 27 October 2025 - 4basebio PLC (AIM: 4BB), an innovation-led
provider of novel synthetic DNA products announces that, following
Investigational New Drug (IND) approval from the FDA, a global Tier 1
pharmaceutical partner has begun dosing patients with an mRNA product
developed using 4basebio’s proprietary opDNA® template. The Company signed
the supply agreement with the partner in April 2024. Specific details of the
clinical trial are not able to be disclosed at this time due to innovator
confidentiality.

The opDNA® template, one of four application-specific DNA templates developed
by 4basebio, supports mRNA invitro transcription (IVT) processes and offers
significant cost, purity and timeline advantages against the incumbent plasmid
DNA.

These clinical achievements follows 4basebio receiving the GMP certification
from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) of
its late-phase manufacturing facility in April 2025. These accomplishments
underscore 4basebio’s role as a trusted partner to the global biopharma
industry, delivering high-quality synthetic DNA to power next-generation
therapies.

Synthetic DNA represents a fundamental shift for the life sciences sector.
Unlike traditional plasmid DNA, which is constrained by lengthy manufacturing
timelines and contamination risks, 4basebio’s proprietary technology
platform enables faster, scalable, and cell-free production of DNA templates.
This technology advancement not only accelerates the development timelines for
cell & gene therapies and vaccines but also offers superior safety and
consistency, two critical factors for clinical success.

By removing bottlenecks in DNA supply, 4basebio enables researchers and drug
development innovator companies to bring transformative therapies to patients
more quickly and more safely, with the potential to change lives across
infectious disease, oncology, and rare genetic disorders.

Dr. Heikki Lanckriet, 4basebio CEO, commented                                 
                                                        , “We are delighted
to have supported this leading pharmaceutical innovator in their recent IND
filing and start of their patient dosing trials. This represents another major
regulatory milestone for 4basebio and a clear signal of growing industry
adoption of synthetic DNA in the use of cell and gene therapies and vaccines.

“We are excited to see increasing momentum as a growing number of client
programs advance into the clinic                                              
                                           .”

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse
(Amendment) (EU Exit) Regulations 2019/310.

For further enquiries, please contact:

 4basebio PLC                                                                                                                                                                                                                        +44 (0)12 2396 7943                                                      
 Dr.                                                     Heikki Lanckriet, CEO                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                              
 Cairn Financial Advisers LLP (Nominated Adviser                                                                      )                                                                                                              +44 (0)20 7213 0880                                                      
 Jo Turner / Sandy Jamieson                                                     / Ed Downes                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                              
 Cavendish Capital Markets Limited (                                                                                         Joint                                                                                          Broker)  +44 (0)20 7220 0500                                                      
 Geoff Nash / Nigel Birks                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                              
 RBC Capital Markets (Joint Broker)                                                                                                                                                                                                  +44 (0)                                                    20 7653 4000  
 Kathryn Deegan / Matthew Coakes                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                              

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.



Copyright (c) 2025 PR Newswire Association,LLC. All Rights Reserved